Events
Start of main content
Critical frontiers between immunity and Gene Therapy
Life and Matter Sciences International Symposium October, 27-28, 2009 Pamplona
General information
Venue: Aula Magna CIMA Universidad de Navarra Avda. Pío XII, 55 31008 Pamplona
- All sessions will take place in English
Organized by:
Fundación Ramón Areces
Coordinator/s:
Ignacio MeleroCIMA. Clínica Universitaria de Navarra. Universidad de Navarra. Pamplona. Spain
Cristian SmerdouCIMA. Universidad de Navarra. Pamplona. Spain
Scientific Commitee:
Jesús Prieto, Juan José Lasarte, Pablo Sarobe, Bruno Sangro, Antonio Fontanellas, José Luis Pérez-Gracia, Gloria González-Aseguinolaza y Rubén HernándezCIMA. Clínica Universitaria de Navarra. Universidad de Navarra. Pamplona. Spain
- Description
- Programme
Description
Gene Therapy is based on the transfer of nucleic acids for treatment or prevention of a given disease. The functions of the immune system are critical for the outcome of Gene Therapy. Antibodies and cell-mediated immune mechanisms can either be friends or foes in Gene Therapy: on the one hand, transfer of therapeutic genes is most efficient when delivered by viral vectors, but the hardest obstacle to use viral vectors is their strong immunogenicity. In this regard neutralizing antibodies can preclude readministrations and cellular responses frequently extinguish the expression of the foreign transgene.
- Strategies to thwart undesired immune responses against transgenes and vectors: immunosuppression and tolerance-inducing regimes
- New and more efficacious ways to elicit and sustain pathogen and tumor immunity
In addition, immune system cells can be modified by gene transfer, leading to several strategies that hold therapeutic hope. Transfer of genes into lymphocytes can educate them to recognize tumor or viral antigens in a fashion that instigates their therapeutic function. If reinfused into patients these activated lymphocytes can exert therapeutic effects that are currently being tested in the clinic by pioneering groups. Inherited primary immunodeficiencies due to genetic mutations can be corrected by manipulation of bone marrow stem cells that will differentiate into healthy immune system cells. Finally, immune cells can also be used as vehicles to deliver oncolytic viruses to tumors or metastatic lymph nodes.
Ongoing improvement and refinement of all these techniques is steadily heading to clinical efficacy. These topics will be covered by experts on the interface between Immunology and Gene Therapy, keeping a translational research perspective.
Programme
Tuesday, 27
8:30
Presentation
Raimundo Pérez-Hernández y Torra
Director. Ramón Areces Foundation. Spain.
Luis Montuenga
The Vice President Research. University of Navarra. Spain.
Julio R. Villanueva
The Scientific Council. Ramón Areces Foundation. Spain.
Ignacio Melero
Cristian Smerdou
Coordinators of Symposium.
Chairman:
Jesús Prieto
CIMA. Clínica Universitaria de Navarra. Pamplona. Spain.
8:45
The human immune response in AAV-mediated gene transfer: problems and solutions
Katherine High
The Children's Hospital of Philadelphia.
Howard Hughes Medical Institute. Philadelphia. United States.
9:30
The cellular and molecular basis of brain immune responses
Pedro Lowenstein
Cedars-Sinai Medical Center. University of california, Los Angeles. United States.
10:15
Semliki Forest virus vectors for gene therapy of cancer
Cristian Smerdou
11:00
Break
Chairwoman:
Puri Fortes
CIMA. Pamplona. Spain.
11:15
RNAi, microRNAs, and nucleic acid based therapies
Mark Kay
Stanford University. Palo Alto. United States.
12:00
Working with the immune system rather than against it in the delivery of effective gene therapies for cancer
Richard Vile
Mayo Clinic College of Medicine. Rochester. United States.
12:45
Immunity control and immunity arousal in Gene Therapy
Ignacio Melero
Chairman:
Rubén Hernández-Alcoceba
CIMA. Pamplona. Spain.
15:00
Oncolytic adenoviruses: virocentrics vs immunocentrics
Ramón Alemany
Institut Catalán de Oncología. Barcelona. Spain.
15:45
Mechanism of transcription in coronavirus and vector development
Luis Enjuanes
Centro Nacional de Biotecnología. CSIC. Madrid. Spain.
16:30
Poxvirus vectors as gene delivery systems for the control of human diseases
Mariano Esteban
Centro Nacional de Biotecnología. CSIC. Madrid. Spain.
17:15
Break
Chairman:
Bruno Sangro
Clínica Universitaria de Navarra. Pamplona. Spain.
17:30
New Approaches for the Gene Therapy of Fanconi anemia
Juan Bueren
Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. Madrid.
Centro de Investigación en Red de Enfermedades Raras (CIBER-ER). Spain.
18:15
Gene Therapy approaches for diabetes mellitus
Fátima Bosch
Universidad Autónoma de Barcelona. Spain.
19:00
Gene Therapy of viral hepatitis
Gloria González-Aseguinolaza
CIMA. Pamplona. Spain.
Wednesday, 28
Chairman:
Pablo Sarobe
CIMA. Pamplona. Spain.
08:00
Strategies for cancer and HIV vaccines using cytokines, TLR ligands, and blockade of the NKT regulatory pathway
Jay A. Berzofsky
Center for Cancer Research, National Cancer Institute (NIH). Bethesda. United States.
08:45
Immune modulation by virus-encoded cytokine decoy receptors
Antonio Alcamí
Centro de Biologia Molecular Severo Ochoa. CSIC-UAM. Madrid. Spain.
09:30
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity
David Sancho-Madrid
Cancer Research UK. London Research Institute. United Kingdom.
10:15
Break
Chairman:
Alan Melcher
Cancer Research UK. Leeds. United Kingdom.
10:30
Bringing genetically modified T cell therapies into mainstream medicine
Malcolm Brenner
Baylor College of Medicine. Houston. United States.
11:15
Targeting tumors with genetically enhanced T lymphocytes
Renier J. Brentjens
Memorial Sloan Kettering Cancer Center (MSKCC). New York. United States.
Chairman:
Juan J. Lasarte
CIMA. Pamplona. Spain.
12:45
From bench to bedside and back again: TCR gene immunotherapy for patients with melanoma
Laura Johnson
Duke University Medical Center. Durham. United States.
12:45
Early and effective immunorecovery after family haploidentical hemopoietic transplantation for leukemia by gene-engineered lymphocytes
Claudio Bordignon
Istituto Scientifico Hospital San Raffaele. Milán. Italy.
-
Activities related
-
Projects related
-
News related
-
Publications related
Activities related
-
26
Jun
2024
Conferencias La aventura de la ciencia Madrid, Miércoles 26 de junio de 2024, 19:00 horas
-
13
Feb
2025
17th edition. Cycle of conferences and debates in science Digital Twins: Technological Advances and Application Opportunities Madrid, Thursday, 13 February 2025, 17:30 hours
-
18
Feb
2025
Session New Therapies for the Inflammation Treatment Madrid, Feb 18th, 2025, Tuesday. 4PM
Projects related
- Development and Application of saRNAs for the Treatment of Rare Monogenic Diseases 2024 Senior Researcher : María Luisa Cayuela Fuentes
- CHANNELOSOME RESCUING PEPTIDES IN THE TREATMENT OF ARRHYTHMIAS IN INHERITABLE HEART DISEASES 2024 Senior Researcher : José Jalife Research Centre or Institution : Centro Nacional de Investigaciones Cardiovasculares (CNIC). Madrid
- Mechanisms for sustaining mitochondrial genome integrity and function during hematopoiesis. 2024 Senior Researcher : Ana Victoria Lechuga Vieco Research Centre or Institution : Fundació Clínic per a la Recerca Biomèdica. Hospital Clínic. Barcelona
News related
Publications related
End of main content